Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy

Prostate

Volumn 72, Issue 11, 2012, Pages 1207-1213

  Komatsu, Shuichi ^a   Hara, Noboru ^a   Ishizaki, Fumio ^a   Nishiyama, Tsutomu ^a   Takizawa, Itsuhiro ^a   Isahaya, Etsuko ^a   Kawasaki, Takashi ^b   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

body fat; androgen deprivation therapy; interleukin 6; sex steroids

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; ESTRADIOL; FLUTAMIDE; GOSERELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; SEX HORMONE BINDING PROTEIN; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY COMPOSITION; BODY FAT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISORDERS OF LIPID METABOLISM; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

AGED; ANDROGEN ANTAGONISTS; BODY COMPOSITION; GONADAL STEROID HORMONES; HUMANS; INTERLEUKIN-6; LIPID METABOLISM DISORDERS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862906442     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22471     Document Type: Article

References (28)

1. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR,. Management of complications of prostate cancer treatment. CA Cancer J Clin 2008; 58: 196-213.
2. Gilbert SM, Kuo YF, Shahinian VB,. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol 2011; 29: 647-653.
3. Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K,. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): Impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. Prostate 2010; 70: 155-161.
4. Berruti A, Dogliotti L, Terrone C, Cerutti S, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A, Group Onco Urologico Piemontese (G.O.U.P), Rete Oncologica Plemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-2367.
5. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
6. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW,. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.
7. Eri LM, Urdal P, Bechensteen AG,. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995; 154: 100-104.
8. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B,. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342.
9. Sopasakis VR, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz M, Yang X, Jansson PA, Smith U,. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 2004; 12: 454-460.
10. Sewter CP, Digby JE, Blows F, Prins J, O'Rahilly S,. Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol 1999; 163: 33-38.
11. Fried SK, Bunkin DA, Greenberg AS,. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850.
12. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW,. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
13. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW,. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-2282.
14. Prins JB, Niesler CU, Winterford CM, Bright NA, Siddle K, O'Rahilly S, Walker NI, Cameron DP,. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes 1997; 46: 1939-1944.
15. Laurencikiene J, van Harmelen V, Arvidsson Nordström E, Dicker A, Blomqvist L, Näslund E, Langin D, Arner P, Rydén M,. NF-kappaB is important for TNF-alpha-induced lipolysis in human adipocytes. J Lipid Res 2007; 48: 1069-1077.
16. Kramer PR, Kramer SF, Guan G,. 17b-Estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum 2004; 50: 1967-1975.
17. Kanda N, Tsuchida T, Tamaki K,. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1703-1711.
18. D'Agostino P, Milano S, Barbera C, Di Bella G, La Rosa M, Ferlazzo V, Farruggio R, Miceli DM, Miele M, Castagnetta L, Cillari E,. Sex hormones modulate inflammatory mediators produced by macrophages. Ann N Y Acad Sci 1999; 876: 426-429.
19. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML,. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179: 1354-1360.
20. Joy T, Kennedy BA, Al-Attar S, Rutt BK, Hegele RA,. Predicting abdominal adipose tissue among women with familial partial lipodystrophy. Metabolism 2009; 58: 828-834.
21. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F,. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-612.
22. Molina A, Belldegrun A,. Novel therapeutic strategies for castration resistant prostate cancer: Inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011; 185: 787-794.
23. Corcoran MP, Meydani M, Lichtenstein AH, Schaefer EJ, Dillard A, Lamon-Fava S,. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol 2010; 206: 217-224.
24. Maggio M, Ceda GP, Lauretani F, Bandinelli S, Corsi AM, Giallauria F, Guralnik JM, Zuliani G, Cattabiani C, Parrino S, Ablondi F, Dall'aglio E, Ceresini G, Basaria S, Ferrucci L,. SHBG, sex hormones, and inflammatory markers in older women. J Clin Endocrinol Metab 2011; 96: 1053-1059.
25. Hoppé E, Bouvard B, Royer M, Audran M, Legrand E,. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine 2010; 77: 306-312.
26. Heinlein CA, Chang C,. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 2002; 16: 2181-2187.
27. Lewis JG, Borowski KK, Shand BI, George PM, Scott RS,. Plasma sex hormone-binding globulin, corticosteroid-binding globulin, cortisol, and free cortisol levels in outpatients attending a lipid disorders clinic: A cross-sectional study of 1137 subjects. Horm Metab Res 2010; 42: 274-279.
28. Duvnjak L, Duvnjak M,. The metabolic syndrome-An ongoing story. J Physiol Pharmacol 2009; 60 (Suppl 7): 19-24.